Optimization of antimicrobial therapy in critically ill patients, what clinicians and searchers must know
Abstract
Effective sepsis treatment requires not only the timely administration of appropriate antimicrobials but also precise dosing to maximize patient survival in intensive care units (ICUs). However, the pharmacokinetics (PK) and pharmacodynamics (PD) of antibiotics in critically ill patients differ significantly from those in the general population. Understanding these pathophysiological changes is essential for optimizing antibiotic therapy. In this context, adequate dosing refers to strategies that achieve therapeutic drug concentrations at the infection site, ensuring both clinical and microbiological effectiveness while minimizing the risk of antibiotic-related toxicity. Additionally, optimizing the mode of antibiotic administration-particularly for beta-lactams-through continuous infusion has shown benefits, including improved achievement of PK/PD targets, higher clinical cure rates, and better microbiological eradication. To ensure proper antimicrobial dosing, therapeutic drug monitoring (TDM) is the preferred approach. However, TDM is not universally available in all ICUs or for all antimicrobial agents. In its absence, clinicians must rely on factors such as the patient's clinical condition, the identified pathogen, the impact of organ dysfunction requiring extracorporeal therapies, and the physicochemical properties of antimicrobials to guide dosing decisions. The pharmacokinetics of antimicrobials can vary widely between critically ill patients and even within the same patient throughout their ICU stay, emphasizing the need for individualized dosing strategies and dynamic reassessments. This review aims to outline the key pathophysiological changes observed in critically ill patients and their influence on antimicrobial dosing decisions, while also providing practical considerations to help clinicians optimize antimicrobial therapy in this patient population. Finally, the outstanding challenges in delivering optimal antimicrobial therapy to critically ill patients will be explored, highlighting areas for future research.
Related
- Evaluation of Model-Informed Precision Dosing of Cefepime in Critically Ill Patients: A French Before–After Study
- CSF pharmacokinetics-pharmacodynamics of linezolid in critically brain injured patients, with or without central nervous system healthcare-associated infection. The PK-Pop-LCR Study: A Multicentre Pharmacokinetics and Pharmacodynamics Population Study
- Responsible use of new antibiotics for critically ill patients suffering from infections due to carbapenem-resistant organisms—a narrative review for an enablement strategy
- Monitoring latent viral reactivation in critically ill patients: a review of immunopathology and emerging diagnostics
- Protein Binding Determination of Cefepime, Flucloxacillin, Meropenem, Piperacillin and Tazobactam by Ultrafiltration in Critically Ill Patients: The Choice of Device Matters
BibTeX
@article{roger2026optimization,
title = {{Optimization of antimicrobial therapy in critically ill patients, what clinicians and searchers must know}},
author = {Claire Roger and Despoina Koulenti and Emmanuel Novy and Jason Roberts and Claire Dahyot-Fizelier},
journal = {Anaesthesia Critical Care \& Pain Medicine},
year = {2026},
month = oct,
doi = {10.1016/j.accpm.2025.101561},
url = {https://hal.science/hal-05642331v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Optimization of antimicrobial therapy in critically ill patients, what clinicians and searchers must know
AU - Claire Roger
AU - Despoina Koulenti
AU - Emmanuel Novy
AU - Jason Roberts
AU - Claire Dahyot-Fizelier
PY - 2026
DA - 2026/10/20
JO - Anaesthesia Critical Care & Pain Medicine
DO - 10.1016/j.accpm.2025.101561
UR - https://hal.science/hal-05642331v1
AB - Effective sepsis treatment requires not only the timely administration of appropriate antimicrobials but also precise dosing to maximize patient survival in intensive care units (ICUs). However, the pharmacokinetics (PK) and pharmacodynamics (PD) of antibiotics in critically ill patients differ significantly from those in the general population. Understanding these pathophysiological changes is essential for optimizing antibiotic therapy. In this context, adequate dosing refers to strategies that achieve therapeutic drug concentrations at the infection site, ensuring both clinical and microbiological effectiveness while minimizing the risk of antibiotic-related toxicity. Additionally, optimizing the mode of antibiotic administration-particularly for beta-lactams-through continuous infusion has shown benefits, including improved achievement of PK/PD targets, higher clinical cure rates, and better microbiological eradication. To ensure proper antimicrobial dosing, therapeutic drug monitoring (TDM) is the preferred approach. However, TDM is not universally available in all ICUs or for all antimicrobial agents. In its absence, clinicians must rely on factors such as the patient's clinical condition, the identified pathogen, the impact of organ dysfunction requiring extracorporeal therapies, and the physicochemical properties of antimicrobials to guide dosing decisions. The pharmacokinetics of antimicrobials can vary widely between critically ill patients and even within the same patient throughout their ICU stay, emphasizing the need for individualized dosing strategies and dynamic reassessments. This review aims to outline the key pathophysiological changes observed in critically ill patients and their influence on antimicrobial dosing decisions, while also providing practical considerations to help clinicians optimize antimicrobial therapy in this patient population. Finally, the outstanding challenges in delivering optimal antimicrobial therapy to critically ill patients will be explored, highlighting areas for future research.
SN - 2352-5568
ER -